1. At a Glance
HVAX Technologies Ltd is what happens when pharma compliance, HVAC engineering, and Indian project execution decide to form a startup in 2010 and accidentally list on the SME exchange in 2024. With a market cap of ₹232 crore, a current price of ₹835, and a stock P/E of 19.1, HVAX looks deceptively calm—like a consultant who smiles politely while billing you by the minute.
The company just clocked ₹60.6 crore quarterly revenue, ₹4.92 crore PAT, and a 28.5% QoQ profit jump, which sounds heroic until you notice that working capital days have exploded to 146 and debtor days are chilling at 199 like unpaid college friends. ROCE stands at a respectable 22.3%, ROE at 21.3%, and debt-to-equity is a manageable 0.25.
Add a ₹288 crore order book (Dec 2023), of which ₹130 crore is already executed, plus 60% export exposure to Africa and emerging markets, and suddenly this “HVAC cleanroom wala” is doing international jugaad at scale. The price, however, has corrected ~10% in three months and ~17% in six months, suggesting the market is not buying the full optimism… yet. Curious why? Good. Read on.
2. Introduction – Cleanrooms, Dirty Cash Cycles
HVAX Technologies operates in a niche so boring that most investors scroll past it—and that’s usually where money hides. Cleanrooms are not sexy. Nobody brags at weddings about negative pressure zones or ISO-classified panels. But pharma companies will literally shut plants if these things fail. That’s HVAX’s entry ticket.
The company positions itself as a design-to-delivery controlled environment infrastructure provider. Translation: once a pharma company decides to build or upgrade a compliant facility, HVAX shows up with drawings, ducts, panels, HVAC, BMS, validation support, and a very long invoice.
Since listing in October 2024, HVAX has tried to balance growth, execution, and capital discipline. Revenue has grown at ~24% CAGR over 3–5 years, profit at ~40% CAGR, which is no joke for a project-heavy EPC-style business.
But—and there’s always a but—this is a company where cash flow from operations is negative, working capital keeps inflating, and receivables behave like they’re on an African safari. This is not fraud; it’s the classic project business pain. The question is: how much pain is tolerable?
3. Business Model – WTF Do They Even Do?
Imagine a pharma company in Ghana wants a WHO-GMP compliant injectable facility. They call HVAX.
HVAX does not manufacture chillers, AHUs, or panels. Instead, it plays the role of the orchestra conductor—designing layouts, sourcing third-party equipment, integrating systems, installing everything, testing it, validating it, and then walking away… hopefully after getting paid.
Revenue Split (FY23)
- Turnkey projects: 95% – full EPC execution
- Services: 3.5% – consultancy, GAP analysis, validation
This is a project-centric model,
One Response
Pls cover Beardsell in this segment.